Clinical trials: Viremia
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
EBV Infection, EBV Viremia
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
Transplant recipients are treated with immunosuppressive drugs to avoid rejection of the transplanted organ. As the medication impairs the immune response, it also increases the risk of serious infections and cancer in transplant…
- Conditions
- EBV Infection, EBV Viremia, Epstein-Barr Virus Associated Lymphoproliferative Disorder, Post-transplant Lymphoproliferative Disorder
- Trial name
- EVITA (NCT04189835)
- Testing
- EBV DNA in whole blood and plasma
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 509 people
- Sponsor
- University of Aarhus
BK Viremia, BK Nephropathy
Using mTOR Inhibitors in the Prevention of BK Nephropathy
BK virus infections after kidney transplant are increasing and can result in damage to the transplanted kidney. Currently, the universally accepted treatment is to decrease the strength of the antirejection medications but it is…
- Trial name
- NCT01649609
- Testing
- Tacrolimus, Mycophenolate acid, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Chronic Hepatitis B
Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
This study explores the efficacy, safety and tolerability of tenofovir DF (TDF) 300 mg once daily monotherapy versus the combination of emtricitabine 200 mg plus tenofovir DF 300 mg (FTC/TDF) once daily in subjects currently…
- Trial name
- NCT00307489
- Testing
- tenofovir DF, emtricitabine /tenofovir DF
- Where
- 28 sites in United States, France and 2 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study to Monitor Patients With Primary or Early HIV Infection
The purpose of this study is to monitor patients who recently have been infected with HIV in order to learn how their immune systems respond to HIV infection and to study how the virus acts in their bodies.
- Trial name
- NCT00000911
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)
This study will look to see if increasing the standard dose of Kaletra is tolerated and if it will lower viral loads to undetectable levels.
- Trial name
- NCT00414284
- Testing
- Increased dose of Kaletra
- Where
- United States
- Sponsor
- Community Research Initiative of New England
HIV-1 Infection
Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
Viral eradication in selected HIV-infected patients is possible with intensive antiretroviral therapy plus immunomodulation
- Trial name
- ERAMUNE-01 (NCT01019551)
- Testing
- ART Intensification, Immunomodulation
- Where
- 5 sites in France, Italy and 2 more
- Volunteers
- 29 people
- Sponsor
- Objectif Recherche Vaccins SIDA
CMV Infection, Cytomegalovirus Infections
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
The present trial will consist of the treatment of 20 pediatric and adult Hematopoietic Stem Cell Transplantation (HSCT) recipients or immunocompromised participants diagnosed with opportunistic Cytomegalovirus (CMV) infections…
- Conditions
- CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
- Trial name
- NCT03798301
- Testing
- CMV-specific T-cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
HIV-1-infection, ART
Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia
This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving…
- Conditions
- HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection
- Trial name
- NCT05700630
- Testing
- FT538, Vorinostat
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
Sepsis, Sepsis Bacterial
Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis
This observational cohort study aims to compare clinical outcomes and inflammatory responses between patients with viral sepsis, specifically COVID-19-associated sepsis, and those with bacterial sepsis.
- Conditions
- Sepsis, Sepsis Bacterial, Viral Sepsis, Inflammatory Response
- Trial name
- NCT06491966
- Testing
- observation
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sichuan Provincial People's Hospital
Viraemia
CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response
The purpose of this study is to see how well the antibody levels found months to years after patients entered a previous randomised placebo-controlled trial of a glycoprotein B vaccine against cytomegalovirus have persisted and…
- Trial name
- NCT01883206
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
HIV Infections
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in vitro activity against HIV-1 strains including those resistant to currently available antiretroviral drugs.
- Trial name
- NCT00515827
- Testing
- Raltegravir (MK-0518)
- Where
- 20 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Viraemia
Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)
This study aims to determine: a) whether those patients with 'low level' viral load results (between 200 and 3,000 copies/ml) could be monitored as opposed to starting preemptive therapy with valganciclovir, ganciclovir and/or…
- Trial name
- NCT00947141
- Testing
- ganciclovir (start when CMV PCR >200copies / ml x2), Monitor (Treatment starts when CMV PCR >3,000 copies / ml), Stop treatment when 2 levels CMV PCR <3,000 copies / ml
- Where
- United Kingdom
- Volunteers
- 165 people
- Sponsor
- University College, London
HIV Infection
"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
Lopinavir/ritonavir monotherapy may maintain virologic suppression in patients who have been undetectable for six months while on triple drug antiretroviral therapy.
- Trial name
- NCT00114933
- Testing
- Stopping nucleosides and continuing lopinavir/ritonavir monotherapy
- Where
- 28 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Arribas, Jose R., M.D.
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Dengue
A Controlled Human Infection Model of Dengue
This study aims to conduct a safe human infection challenge using an attenuated serotype DEN3 dengue virus in adult volunteers. The clinical, viral and immune response characteristics of the model will be analysed to understand…
- Trial name
- DEN-CHIM-01 (NCT07412483)
- Testing
- GMP-produced rDEN3delta30 virus
- Where
- Singapore
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
HIV Infection
Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia
The medicines used to treat HIV can suppress but cannot kill all the virus in the body. A small amount of virus remains at low levels in the part of the blood called the plasma.
- Trial name
- NCT00618371
- Testing
- Raltegravir (MK-0518)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh
EBV Viremia
Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients
The NeuMoDx EBV Quant Assay 2.0 study is a multi-center, observational clinical investigation designed to evaluate the performance of the NeuMoDx EBV Quant Assay 2.0 in quantifying Epstein-Barr virus (EBV) DNA levels in plasma…
- Trial name
- NCT06681025
- Testing
- NeuMoDx EBV Quant 2.0 Assay
- Where
- United Kingdom
- Volunteers
- 1,070 people
- Sponsor
- QIAGEN Gaithersburg, Inc
HIV Infections
Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus
Drug resistance may develop in HIV infected patients who take anti-HIV drugs, but most patients do well if they continue taking them.
- Trial name
- NCT00102934
- Testing
- Enfuvirtide-intensified HAART
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, Heart Transplantation
Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)
Context Cytomegalovirus (CMV) infection is a frequent and potentially severe event in solid organ transplant (SOT) recipients. Most of available treatment display adverse effects that limit their use.
- Conditions
- Cytomegalovirus Infections, Heart Transplantation, Kidney Transplantation, Lung Transplantation
- Trial name
- QUANTIFOT (NCT06341543)
- Testing
- Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes)., Communication of the result of the QF-CMV to the clinician in charge
- Where
- France
- Volunteers
- 288 people
- Sponsor
- University Hospital, Grenoble